CXCL5 Antikörper (PE)

Produktnummer ABIN2662704

Dieses Maus Monoklonal-Antikörper erkennt spezifisch CXCL5 in FACS. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für CXCL5 Antikörper (PE) (ABIN2662704)

Target: CXCL5 (Chemokine (C-X-C Motif) Ligand 5 (CXCL5))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CXCL5 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Klon: J111B7

Produktdetails anti-CXCL5 Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu CXCL5

Target: CXCL5 (Chemokine (C-X-C Motif) Ligand 5 (CXCL5))

Andere Bezeichnung: CXCL5

Hintergrund: CXCL5, also known as ENA-78, is a 11.9 kD chemokine and belongs to the intercrine alpha, CXC chemokine family. It is expressed by monocytes and eosinophils in response to IL-1 and TNFα. CXCL5 can interact with CXCR2 and activate neutrophils and induce their migration. In vitro neutrophil chemotactic activity of CXCL5 is three fold higher. IFNγ suppresses expression of CXCL5. NFκB alone is sufficient to induce CXCL5 in contrast to IL-8, which requires both NFκB and C/EBP. Two forms are produced by N terminal proteolytic cleavage, ENA78 (8-78) and ENA 78 (9-78), and these isoforms exhibit higher chemotactic activity. Increased intra-hepatic levels of CXCL5 have been reported in patients with chronic liver disease.

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity